section name header

Pronunciation

PIN-doe-lole

Classifications

Therapeutic Classification: antihypertensives

Pharmacologic Classification: beta blockers

Indications

REMS

Unlabeled Uses:

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Moderate CNS penetration. Crosses the placenta; enters breast milk.

Metabolism/Excretion: Partially metabolized by the liver; 50% excreted unchanged by the kidneys.

Half-life: 3–4 hr.

Time/Action Profile

(cardiovascular effects)

ROUTEONSETPEAKDURATION
PO7 days2 wk8–24 hr

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: HF, ARRHYTHMIAS, BRADYCARDIA, orthostatic hypotension, peripheral vasoconstriction, PULMONARY EDEMA.

Derm: itching, rashes.

EENT: blurred vision, dry eyes, nasal stuffiness.

Endo: hyperglycemia, hypoglycemia.

GI: constipation, diarrhea, nausea.

GU: erectile dysfunction, libido.

MS: arthralgia, back pain, muscle cramps.

Neuro: fatigue, weakness , anxiety, depression, dizziness, drowsiness, insomnia, memory loss, mental status changes, nervousness, nightmares, paresthesia.

Resp: bronchospasm, wheezing.
Misc: drug-induced lupus syndrome.

Interactions

Drug-Drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Visken

Canadian Brand Names

Visken